EGFR and non-small cell lung carcinoma: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) have demonstrated dramatic efficacy for EGFR-mutated non-small cell lung cancer (NSCLC), however, acquired drug resistance inevitably occurs at a median time of approximately 12 to 20 months during targeted therapy [1–4].